Literature DB >> 25391769

Frequency of interleukin 28B rs12979860 C>T variants in Filipino patients chronically infected with hepatitis B virus.

Michael O Baclig1, Karen G Reyes, Cynthia A Mapua, Juliet Gopez-Cervantes, Filipinas F Natividad.   

Abstract

Hepatitis B virus (HBV) is one of the most prevalent viral infections worldwide. Nearly 400 million individuals are chronic carriers of HBV. The aim of the present study was to determine the frequency of human interleukin 28B (IL28B) variants among treatment naive Filipino patients clinically diagnosed with chronic hepatitis B (CHB), and to compare the IL28B frequency distribution with various ethnic populations. Fifty-seven CHB patients and 43 normal controls were enrolled in this study. Real-time PCR was performed using the TaqMan genotyping assay for IL28B rs12979860. The allelic frequencies among normal controls were 0.94 and 0.06 for the IL28B rs12979860 C and T alleles, respectively. Eighty-eight percent were identified as homozygous for the IL28B C/C genotype and 12% were identified as heterozygous for the IL28B C/T genotype. Among CHB patients, the allelic frequencies were 0.90 for the IL28B C allele and 0.10 for the IL28B T allele. No IL28B T/T genotype was observed between the two groups. No significant difference in the distribution of IL28B genotypes was observed between normal controls and CHB patients. Allelic frequencies of IL28B among Filipinos were similar with other Asian populations but significantly different from Caucasians. The frequency of rs12979860 C>T variants among Filipino CHB patients has not yet been reported. These data provided new insight into the geographical frequency distribution of IL28B variants. Further studies are needed to determine the possible association between IL28B variants and response to pegylated-interferon-α plus ribavirin combination therapy among Filipino patients chronically infected with HBV.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25391769     DOI: 10.1007/s11033-014-3814-1

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  40 in total

1.  A straightforward genotyping of the relevant IL28B SNPs for the prediction of hepatitis C treatment outcome.

Authors:  Simone Moreira; Raquel Francine Liermann Garcia; Andréia Gutberlet; Bruna Cristina Bertol; Leslie Ecker Ferreira; Mauro de Souza Leite Pinho; Paulo Henrique Condeixa de França
Journal:  J Virol Methods       Date:  2012-06-01       Impact factor: 2.014

Review 2.  Genetics of IL28B and HCV--response to infection and treatment.

Authors:  C Nelson Hayes; Michio Imamura; Hiroshi Aikata; Kazuaki Chayama
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-29       Impact factor: 46.802

3.  Development of new IL28B genotyping method using Invader Plus assay.

Authors:  Satomi Kani; Yasuhito Tanaka; Kentaro Matsuura; Tsunamasa Watanabe; Hiroshi Yatsuhashi; Etsuro Orito; Ken Inose; Nao Motojuku; Yukio Wakimoto; Masashi Mizokami
Journal:  Microbiol Immunol       Date:  2012-05       Impact factor: 1.955

4.  Interleukin-28B genotyping by melt-mismatch amplification mutation assay PCR analysis using single nucleotide polymorphisms rs12979860 and rs8099917, a useful tool for prediction of therapy response in hepatitis C patients.

Authors:  Salvador Fonseca-Coronado; Gilberto Vaughan; Mayra Yolanda Cruz-Rivera; Juan Carlos Carpio-Pedroza; Karina Ruiz-Tovar; Juan Alberto Ruiz-Pacheco; Alejandro Escobar-Gutiérrez
Journal:  J Clin Microbiol       Date:  2011-05-25       Impact factor: 5.948

5.  IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC.

Authors:  Carlo Fabris; Edmondo Falleti; Annarosa Cussigh; Davide Bitetto; Elisabetta Fontanini; Sara Bignulin; Sara Cmet; Ezio Fornasiere; Elisa Fumolo; Stefano Fangazio; Andrea Cerutti; Rosalba Minisini; Mario Pirisi; Pierluigi Toniutto
Journal:  J Hepatol       Date:  2010-09-19       Impact factor: 25.083

6.  Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies.

Authors:  Stuart K Roberts; Joanne Mitchell; Reynold Leung; David Booth; Steven Bollipo; George Ostapowicz; Andrew Sloss; Geoffrey W McCaughan; Gregory J Dore; Alexander Thompson; Darrell Hg Crawford; William Sievert; Martin Weltman; Wendy Cheng; Jacob George
Journal:  J Gastroenterol Hepatol       Date:  2014-01       Impact factor: 4.029

7.  Hepatitis B infection among adults in the philippines: A national seroprevalence study.

Authors:  Stephen N Wong; Janus P Ong; Madalinee Eternity D Labio; Oscar T Cabahug; Maria Lourdes O Daez; Erlinda V Valdellon; Jose D Sollano; Marilyn O Arguillas
Journal:  World J Hepatol       Date:  2013-04-27

8.  Polymorphisms near interleukin 28B gene are not associated with hepatitis B virus clearance, hepatitis B e antigen clearance and hepatocellular carcinoma occurrence.

Authors:  Dong Hyeon Lee; Yuri Cho; Ji Yeon Seo; Jung Hee Kwon; Eun Ju Cho; Eun Sun Jang; Min-Sun Kwak; Jae Youn Cheong; Sung Won Cho; Jeong-Hoon Lee; Su Jong Yu; Jung-Hwan Yoon; Hyo-Suk Lee; Chung Yong Kim; Hyoung Doo Shin; Yoon Jun Kim
Journal:  Intervirology       Date:  2013-01-22       Impact factor: 1.763

9.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962

10.  Genetic variation in interleukin 28B and response to antiviral therapy in patients with dual chronic infection with hepatitis B and C viruses.

Authors:  Xiaoyan Guo; Guilin Yang; Jin Yuan; Peng Ruan; Mingxia Zhang; Xincun Chen; Boping Zhou
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.